Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SI-B001 plus osimertinib in EGFR-mutant NSCLC
NCT05020769Phase 3Active, not recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Jan 2022
- Primary completion
- Dec 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of izalontamab in non-small cell lung cancer (NSCLC), sponsored by Biokin Pharmaceutical. Started Jan 2022; status: active, not recruiting.
02
Drugs
izalontamab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05020769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05020769.